IPO registrations (S-1, F-1) · Registrants
SOLIGENIX, INC.
- SEC CIK
- 812796 · filings on EDGAR ↗
- Former names
- DOR BIOPHARMA INC (2002–2009); ENDOREX CORP (1996–2001); IMMUNOTHERAPEUTICS INC (1995–1996)
- Registration
- Form S-1, first filed 2006-01-20, last 2025-09-19; 18 initial registrations, 25 amendments
- Outcome
- Final prospectus filed 2013-06-21; declared effective 2006-05-26
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 29 EMMONS DRIVE, SUITE B-10, Princeton, NJ 08540
- EIN
- 41-1505029
- Ticker
- SNGX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- SOLIGENIX, INC. on the corporate pages
On this site
- Business registration: DOR BIOPHARMA, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: SOLIGENIX INC EXACT (EIN (EXACT))
- Form D issuer: SOLIGENIX, INC. EXACT (CIK (EXACT))
- SEC filer: DOR BIOPHARMA INC EXACT (CIK (EXACT))
- Person page: Christopher J Schaber Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 102
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-01-20 | S-1 | S-1 (registration) | DOR BIOPHARMA INC | 0000812796-06-000005 ↗ |
| 2006-05-26 | EFFECT | EFFECT (declared effective) | DOR BIOPHARMA INC | 9999999995-06-000099 ↗ |
| 2007-03-20 | EFFECT | EFFECT (declared effective) | DOR BIOPHARMA INC | 9999999995-07-000971 ↗ |
| 2007-04-18 | EFFECT | EFFECT (declared effective) | DOR BIOPHARMA INC | 9999999995-07-001370 ↗ |
| 2008-02-14 | S-1 | S-1 (registration) | DOR BIOPHARMA INC | 0000812796-08-000002 ↗ |
| 2008-04-01 | S-1/A | S-1/A (amendment) | DOR BIOPHARMA INC | 0000812796-08-000013 ↗ |
| 2008-04-04 | EFFECT | EFFECT (declared effective) | DOR BIOPHARMA INC | 9999999995-08-000997 ↗ |
| 2009-02-13 | S-1 | S-1 (registration) | DOR BIOPHARMA INC | 0000812796-09-000009 ↗ |
| 2009-04-14 | S-1/A | S-1/A (amendment) | DOR BIOPHARMA INC | 0000812796-09-000030 ↗ |
| 2009-04-17 | EFFECT | EFFECT (declared effective) | DOR BIOPHARMA INC | 9999999995-09-000981 ↗ |
| 2009-05-06 | EFFECT | EFFECT (declared effective) | DOR BIOPHARMA INC | 9999999995-09-001312 ↗ |
| 2009-10-07 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-09-002746 ↗ |
| 2009-10-19 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-09-002851 ↗ |
| 2009-10-20 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-09-002903 ↗ |
| 2010-04-30 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-10-001273 ↗ |
| 2010-04-30 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-10-001297 ↗ |
| 2010-05-10 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-10-001437 ↗ |
| 2010-06-25 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-10-002634 ↗ |
| 2010-07-09 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-10-002812 ↗ |
| 2010-07-13 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-10-002122 ↗ |
| 2011-04-22 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-11-001124 ↗ |
| 2011-04-22 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-11-001125 ↗ |
| 2011-04-22 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-11-001128 ↗ |
| 2011-04-22 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-11-001132 ↗ |
| 2012-11-05 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-12-005920 ↗ |
| 2013-03-01 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-13-000915 ↗ |
| 2013-05-08 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-13-002294 ↗ |
| 2013-06-13 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-13-003102 ↗ |
| 2013-06-13 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-13-003110 ↗ |
| 2013-06-19 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-13-003214 ↗ |
| 2013-06-20 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-13-001857 ↗ |
| 2013-06-21 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001213900-13-003228 ↗ |
| 2013-06-26 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-13-001920 ↗ |
| 2013-12-17 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-13-007264 ↗ |
| 2013-12-30 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-13-007471 ↗ |
| 2014-01-13 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-14-000185 ↗ |
| 2014-01-15 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-14-000127 ↗ |
| 2014-04-21 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-14-001067 ↗ |
| 2014-05-14 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-14-001454 ↗ |
| 2014-09-30 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-14-007014 ↗ |
| 2014-10-31 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-14-007652 ↗ |
| 2014-11-04 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-14-007716 ↗ |
| 2014-11-05 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-14-003252 ↗ |
| 2014-11-17 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-14-008354 ↗ |
| 2014-12-17 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-14-008947 ↗ |
| 2014-12-18 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-14-003735 ↗ |
| 2014-12-19 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001213900-14-009023 ↗ |
| 2014-12-30 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-14-003906 ↗ |
| 2015-04-06 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-15-000793 ↗ |
| 2015-04-06 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-15-000794 ↗ |
| 2015-04-06 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-15-000798 ↗ |
| 2015-08-03 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-15-005654 ↗ |
| 2015-08-21 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-15-006465 ↗ |
| 2015-08-25 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-15-002372 ↗ |
| 2016-04-08 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-16-012352 ↗ |
| 2016-04-14 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-16-004201 ↗ |
| 2016-04-14 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-16-004203 ↗ |
| 2016-04-14 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-16-004209 ↗ |
| 2016-04-14 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-16-004212 ↗ |
| 2016-04-28 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-16-004374 ↗ |
| 2016-10-07 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-16-017381 ↗ |
| 2016-11-14 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-16-018265 ↗ |
| 2016-11-15 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-16-018555 ↗ |
| 2016-11-21 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-16-018769 ↗ |
| 2016-11-22 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-16-018882 ↗ |
| 2016-11-22 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-16-006297 ↗ |
| 2016-12-13 | S-1MEF | S-1MEF (added securities) | SOLIGENIX, INC. | 0001213900-16-019354 ↗ |
| 2016-12-14 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001213900-16-019425 ↗ |
| 2017-05-03 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-17-001166 ↗ |
| 2017-08-11 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-17-002096 ↗ |
| 2017-11-20 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-17-012407 ↗ |
| 2017-11-30 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-17-003097 ↗ |
| 2018-05-25 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001213900-18-006892 ↗ |
| 2018-06-18 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-18-007821 ↗ |
| 2018-06-20 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001213900-18-007967 ↗ |
| 2018-06-27 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-18-001638 ↗ |
| 2018-06-29 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001213900-18-008458 ↗ |
| 2020-08-28 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-20-002302 ↗ |
| 2021-01-29 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-21-000351 ↗ |
| 2023-03-31 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001558370-23-005321 ↗ |
| 2023-04-20 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001558370-23-006259 ↗ |
| 2023-05-04 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001558370-23-008158 ↗ |
| 2023-05-05 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-23-001321 ↗ |
| 2023-05-08 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001558370-23-008353 ↗ |
| 2023-12-15 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-23-003649 ↗ |
| 2024-01-16 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001558370-24-000253 ↗ |
| 2024-03-15 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001558370-24-003415 ↗ |
| 2024-04-02 | S-1/A | S-1/A (amendment) | SOLIGENIX, INC. | 0001558370-24-004621 ↗ |
| 2024-04-15 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-24-000976 ↗ |
| 2024-04-19 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001558370-24-005363 ↗ |
| 2024-07-24 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001558370-24-010061 ↗ |
| 2024-08-02 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-24-002372 ↗ |
| 2025-03-26 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-25-000785 ↗ |
| 2025-03-26 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-25-000788 ↗ |
| 2025-03-26 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-25-000789 ↗ |
| 2025-09-19 | S-1 | S-1 (registration) | SOLIGENIX, INC. | 0001104659-25-091717 ↗ |
| 2025-09-25 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-25-003103 ↗ |
| 2025-09-26 | 424B4 | 424B4 (final prospectus) | SOLIGENIX, INC. | 0001104659-25-093934 ↗ |
| 2026-04-02 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-26-001056 ↗ |
| 2026-04-02 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-26-001058 ↗ |
| 2026-04-02 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-26-001059 ↗ |
| 2026-04-02 | EFFECT | EFFECT (declared effective) | SOLIGENIX, INC. | 9999999995-26-001064 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Haig Alexander P | Director | 1 | 2006 | ||
| KANZER STEVE H | Director | 4 | 2006–2007 | ||
| KUO JAMES S | Director | 6 | 2006–2009 | ||
| Madison T J | Director | 1 | 2006 | ||
| MYRIANTHOPOULOS EVAN | Director,Officer | CFO and Senior Vice Presient; Chief Financial Officer; Sr VP and CFO | 8 | 2006–2011 | |
| SEMBER MICHAEL T | Director,Officer | Chief Executive Officer | 2 | 2006 | |
| Clavijo James | Officer | Controller/Treasurer | 5 | 2006–2008 | |
| SCHABER CHRISTOPHER J | Director,Officer; Officer | Chairman CEO and President; Chairman, CEO and President; CHAIRMAN, CEO AND PRESIDENT; Chairman, CEO & President; Chief Executive Officer; President and CEO | 44 | 2006–2025 | person page Fuzzy |
| Buhrman Cyrille F | Director | 4 | 2007–2009 | ||
| CAVAZZA CLAUDIO | TenPercentOwner | 4 | 2008–2010 | ||
| CAVAZZA PAOLO | Other; TenPercentOwner | 6 | 2008–2017 | ||
| Essetifin SPA | Other; TenPercentOwner | 6 | 2008–2017 | ||
| Leadiant Biosciences, Inc. | Other; TenPercentOwner | 6 | 2008–2017 | ||
| Sigma-Tau America S.A. | TenPercentOwner | 5 | 2008–2012 | ||
| SIGMA TAU INTERNATIONAL SA | TenPercentOwner | 5 | 2008–2012 | ||
| Hamilton Brian L | Officer | Chief Medical Officer; Chief Medical Officer & Sr VP | 3 | 2009–2010 | |
| LAPOINTE ANTHONY GREGG | Director | 22 | 2009–2026 | ||
| Brey Robert N | Officer | Chief Science Officer & Sr VP; Chief Scientific Officer/SrVP; Chief Scientific Offr & Sr. VP; Chief Scientific Off., Sr. VP; Sr VP & Chief Science Officer | 6 | 2009–2013 | |
| Biotex Pharma Investments, LLC | TenPercentOwner | 5 | 2009 | ||
| SCHNITTKER CHRISTOPHER P | Officer | VP-Admin., Controller; VP ADMIN CONTROLLER | 3 | 2009–2010 | |
| RUBIN ROBERT J. | Director | 21 | 2009–2026 | ||
| BAM Management LLC | TenPercentOwner | 2 | 2010 | ||
| Berman Ross | TenPercentOwner | 2 | 2010 | ||
| Mintz Hal | TenPercentOwner | 2 | 2010 | ||
| HOWSON TAMAR D | Director | 3 | 2010–2011 | ||
| THOMPSON VIRGIL | Director | 3 | 2010–2011 | ||
| HORGAN KEVIN | Officer | Chief Medical Officer & Sr. VP; Senior VP; Chief Med Officer; Sr VP, Chief Medical Officer | 4 | 2011–2013 | |
| Warusz Joseph Michael | Officer; OfficerOther | VP of Admin, Controller; VP of Admin, Controller / PAO; VP of Finance & Acting CFO; VP of Finance/Acting CFO; VP of Finance and Acting CFO | 9 | 2011–2016 | |
| Brownlie Keith L | Director | 12 | 2011–2018 | ||
| ZELDIS JEROME B | Director | 25 | 2011–2026 | ||
| INTREXON CORP | TenPercentOwner | 2 | 2013–2017 | ||
| KIRK RANDAL J | TenPercentOwner | 2 | 2013–2017 | ||
| Brughera Marco Maria | Director | 8 | 2013–2017 | ||
| Straube Richard | Officer | CMO; CMO (Consulting); SENIOR VICE PRESIDENT AND CMO; Senior VP and CMO; Senior VP & CMO; Sr VP & Chief Medical Officer; SVP and CMO | 15 | 2014–2025 | |
| Donini Oreola | Officer | CSO; Senior Vice President and CSO; SVP and CSO | 12 | 2014–2025 | |
| Krumeich Karen R | Officer | SVP and CFO | 5 | 2016–2018 | |
| Cavazza Enrico | Other | 1 | 2017 | ||
| Cavazza Francesca | Other | 1 | 2017 | ||
| Cavazza Preta Martina | Other | 1 | 2017 | ||
| Cavazza Silvia | Other | 1 | 2017 | ||
| Pearson Mark E. | Director; Director,TenPercentOwner | 6 | 2018–2019 | ||
| Parks Diane L. | Director | 12 | 2019–2026 | ||
| Guarino Jonathan L. | Officer | CFO; Chief Financial Officer; CHIEF FINANCIAL OFFICER; Senior Vice President and CFO; Senior Vice President & CFO | 12 | 2019–2025 | |
| Cote Timothy R. | Director | 2 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-11-08 | SOLIGENIX, INC. | Pharmaceuticals | $1,964,000 | $1,964,000 | 6 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.